Mithramycin Treatment of Intractable Hypercalcemia Due to Parathyroid Carcinoma
- 17 September 1970
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 283 (12) , 634-636
- https://doi.org/10.1056/nejm197009172831206
Abstract
MITHRAMYCIN, a cytotoxic antibiotic used mainly in the therapy of embryonal tumors of the testis,1 2 3 4 5 has been stated to lower serum calcium levels even in normocalcemic patients.2 , 6 , 7 Its toxic side effects, particularly excessive bleeding, have restricted its reported use to patients with various cancers,1 2 3 4 5 6 , 8 9 10 11 12 13 14 one patient with hyperparathyroidism14 and short-term studies in two patients with Paget's disease of bone.7 We recently administered this drug† to a patient with metastatic parathyroid carcinoma and severe osteitis fibrosa cystica whose hypercalcemia, bone pain and related symptoms could not be controlled by surgical or intensive medical therapy. The drug acutely lowered plasma calcium to . . .Keywords
This publication has 12 references indexed in Scilit:
- Mithramycin treatment of hypercalcemiaCancer, 1970
- Effects of Mithramycin on Paget's Disease of BoneAnnals of Internal Medicine, 1969
- Mithramycin treatment of malignant hypercalcaemia.BMJ, 1968
- A clinical trial of mithramycin in the treatment of advanced malignant diseaseBritish Journal of Cancer, 1968
- Mithramycin in Metastatic Urogenital CancerJournal of Urology, 1967
- Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.BMJ, 1967
- A trial of mithramycin in the treatment of advanced malignant disease.British Journal of Cancer, 1966
- Specific effect of mithramycin on embryonal carcinoma of the testisCancer, 1965
- Mithramycin in the Treatment of Disseminated Testicular NeoplasmsNew England Journal of Medicine, 1965
- Mithramycin in the treatment of embryonal cancerCancer, 1964